A Randomized Phase II Study of the Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy and 5FU/capecitabine with and without Zometa in Patients with Locally Advanced Pancreatic Adenocarcinoma Cancer
Categories (click each to see list of all clinical trials associated with that category): GI (ONC), Radiation Oncology (RADONC)
Current Status: Open
Phase: II (Cancer Control)
Principal Investigator: Lin, Chi
Contact Information:
Amanda Fulton
402-552-2790
amfulton@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT03073785?term=NCT03073785&rank=1
Summary
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of hypofractionated radiation therapy concurrently with zoledronic acid (Zometa) and fluorouracil (5Fu) or capecitabine.
SECONDARY OBJECTIVES:
I. To examine the toxicity of Zometa while it is used concurrently with hypofractionated radiation therapy.
II. To evaluate local failure-free survival and overall survival, surgical resection rate and tumor response rate.